Physician profile
Jane A Johnson
NPI 1427132877
$17,655.73
in general payments reported to CMS, 2019-2025
53 companies · $3,311 in 2025
The $3,311 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,187 · 2020: $1,074 · 2021: $2,477 · 2022: $2,961 · 2023: $3,257 · 2024: $3,389 · 2025: $3,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,957.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,184.13 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,890.14 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,063.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $1,036.78 | 2021-2025 | |
| Glaxosmithkline, LLC. | $956.07 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $892.99 | 2019-2025 | |
| Novo Nordisk INC | $873.08 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $739.83 | 2020-2025 | Repatha, Krystexxa, Otezla |
| Supernus Pharmaceuticals, INC. | $666.19 | 2019-2023 | Qelbree |
| Merck Sharp & Dohme LLC | $600.01 | 2019-2025 | Verquvo, Steglatro, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $567.07 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $508.37 | 2021-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $416.29 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $392.03 | 2021-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $354.51 | 2023-2025 | Gemtesa |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $344.25 | 2022-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $343.87 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $280.73 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $272.40 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $269.27 | 2019-2024 | Trintellix |
| Vanda Pharmaceuticals INC. | $266.11 | 2024-2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.29 | 2020-2025 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $242.46 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Alkermes, INC. | $237.77 | 2022-2025 | Aristada, Vivitrol, Lybalvi |
| Mylan Specialty L.P. | $215.98 | 2021-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $198.02 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $148.95 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $145.37 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $145.22 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $142.99 | 2024 | Inpefa |
| Scilex Pharmaceuticals INC. | $136.43 | 2021-2024 | |
| Allergan, INC. | $102.27 | 2019-2020 | |
| Abbott Laboratories | $100.76 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Corcept Therapeutics | $74.78 | 2025 | Korlym |
| Evoke Pharma, INC. | $69.59 | 2022-2025 | |
| Reflow Medical INC | $65.83 | 2025 | |
| Xeris Pharmaceuticals, INC. | $61.34 | 2021-2025 | Gvoke Hypopen |
| Collegium Pharmaceutical, INC. | $60.24 | 2024 | Belbuca |
| Currax Pharmaceuticals LLC | $44.33 | 2021-2022 | |
| Zyla Life Sciences, INC. | $38.85 | 2020 | |
| Tolmar, INC. | $31.13 | 2024 | |
| Sanofi-Aventis U.S. LLC | $24.64 | 2021 | |
| Pulmonx Corporation | $21.45 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Ucb, INC. | $20.94 | 2024 | Nayzilam |
| Amarin Pharma, INC. | $20.06 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.44 | 2024 | Zoryve |
| Becton, Dickinson and Company | $18.10 | 2020 | |
| Gilead Sciences, INC. | $17.18 | 2023 | |
| Alexion Pharmaceuticals, INC. | $15.84 | 2022 | |
| Eisai INC. | $14.25 | 2021 | |
| Dexcom, INC. | $14.22 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.30 | 2019 | |
| Owp Pharmaceuticals, INC. | $13.24 | 2023 | Lamotrigine, Subvenite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.